1 / 10

Tesheia H. Johnson, MBA October 30, 2007

Yale Center for Clinical Investigation: Academic Home to the CTSA Secretary’s Advisory Committee on Human Research Protections (SACHRP) Presentation. Tesheia H. Johnson, MBA October 30, 2007. Yale University School of Medicine. Major Programmatic Goals of CTSA Program.

forest
Télécharger la présentation

Tesheia H. Johnson, MBA October 30, 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Yale Center for Clinical Investigation: Academic Home to the CTSASecretary’s Advisory Committee on Human Research Protections (SACHRP) Presentation Tesheia H. Johnson, MBA October 30, 2007 Yale University School of Medicine

  2. Major Programmatic Goals of CTSA Program • Regulatory Support for research teams to protect human subjects and facilitate regulatory compliance. • To create a true “One Stop Shopping” for all resources needed for the design, implementation & oversight of clinical and translational research studies. CTSA Regulatory Knowledge Working Group Priority Areas: • Define and develop the mission, scope and model for the Research Subject Advocacy (RSA) role in the CTSA. • Define and develop the mission, scope and model for the Clinical Research Coordinator (CRC) role in the CTSA. • Facilitate IND/IDE support for the CTSAs • Facilitate understanding of the changing CMS regulations and the impact on regulatory activities

  3. The Local Setting The CTSA Opportunity • To consolidate the review process • Work collaboratively with University Compliance and Contracting Offices • Work collaboratively with other categorical centers for the benefit of clinical researchers Challenges/ Roadblocks • Developing a structure that will maximize subject safety and allow for data collection for tracking purposes, without developing institutional processes which will be burdensome to investigators

  4. The Local Setting, continued The CTSA Opportunity • Encourage compliance through facilitating the research process • Take on non- Human Subject Safety functions like IND • Work collaboratively on a centralized electronic system for all review functions Challenges/ Roadblocks • The IRB has become a institutional gate keeper of many non- human subject safety issues. The challenge is to now define institutional roles: • What should exist as a function of the center? • What should be an IRB function? “IRB Mission creep”

  5. US Reduction in the Market Share: Sources of 1572 filings Source: Thomson CenterWatch Analysis 2006; FDA, 2006

  6. Causes of Study Initiation DelaysUnited States Source: Thomson CenterWatch 2003 (n=396); 2005 (n=612) Survey of Investigative Sites in the U.S.

  7. The National Setting The CTSA Opportunity • Testing ground for new models of review • Learn from others: Industry experience with commercial IRBs, NCI experience with central IRB, etc • Work collaboratively with other categorical centers for the benefit of clinical researchers • Develop support models for non-safety functions Challenges/ Roadblocks to the Human Subjects System • Multi-center studies • Each institution has a separate review • Within an institution a study may have 4 to 5 internal reviews prior to approval • Institutional IRBs require faculty service time • “What will this do for my career?” • IRB is responsible for safety – Who takes on the other issues

  8. The National Setting , continued The CTSA Opportunity • CTSA and NIH working collaboratively with clinical research stakeholders (FDA, OHRP, research community, etc) • Cross NIH expertise • Developing new structure that will facilitate research (training, regulatory, study support) • Best practices for study implementation and conduct • Marketing to public at a national level on the merits of clinical research Challenges/ Roadblocks to the Human Subjects System • In addition to multiple reviews, researcher are subject to multiple audits often with conflicting requirements • Short life of the research career • Negative public perceptions of clinical research

  9. CTSA as a Testing Ground for New Models of Review Grant Year One: • Initiation of an Alternative IRB workgroup • First meeting of the regulatory workgroup of the 2006 CTSAs Grant Year Two: • Project development for Alternative IRB workgroup • Regulatory workgroup to begin projects • Metrics of study implementation timelines to be collected

  10. Long-Term Regulatory Goals for the CTSAs • Regulatory training of clinical investigators and staff • Best practices in the protection of human subjects participating in research • Promote clinical and interdisciplinary research by streamlining the initiation and regulatory process

More Related